Microcap Ledger Unicycive Therapeutics, Inc. $UNCY
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Mountain View, CA
- Fiscal year end
- December 31
- Shares outstanding
- 27,855,257 [10-Q 2026-08-12]
What the company doesAI summary of filing
Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for kidney disease. The company's two product candidates are oxylanthanum carbonate, a next-generation phosphate binder for treating hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a novel drug candidate in development for acute kidney injury. Oxylanthanum carbonate has completed clinical trials and an NDA was resubmitted to the FDA in December 2025 with a target action date of June 29, 2026; UNI-494 completed a Phase 1 study in 2024. The company generates no product revenue to date and relies on licensing and developing assets acquired from third parties, with plans to commercialize OLC in the U.S. and partner with global companies in other markets. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$14.54M | −$13.85M | $44.19M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | — | −$26.55M | −$31.32M | $29.20M | [10-K 2026-03-30] |
| FY ended Dec 2024 | — | −$36.73M | −$28.57M | $26.14M | [10-K 2026-03-30] |
- Quarterly cash burn
- −$6.92M
- Cash runway Estimate
- ~19.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-13 | 103,796,406 | [10-Q 2024-11-13] |
| 2025-03-28 | 119,705,026 | [10-K 2025-03-31] |
| 2025-05-14 | 120,629,281 | [10-Q 2025-05-14] |
| 2025-08-14 | 17,661,698 | [10-Q 2025-08-14] |
| 2025-11-12 | 21,491,396 | [10-Q 2025-11-12] |
| 2026-03-30 | 25,237,782 | [10-K 2026-03-30] |
| 2026-05-12 | 26,700,027 | [10-Q 2026-05-12] |
| 2026-08-12 | 27,855,257 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2026-06-05; declared effective 2026-06-15 [S-3 2026-06-05]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 8-K | Director or officer change; Other events |
| 2026-09-28 | 8-K | Other events |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 8-K | Results of operations |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-07-30 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-08 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-02 | 8-K | Other events |
| 2026-06-22 | 8-K | Shareholder vote results |
| 2026-06-05 | 8-K | Material agreement entered |
| 2026-06-05 | S-3 | Registration statement |
Alerts for $UNCY
Email me when Unicycive Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.